Trial Profile

A Phase 3b Open-label Extension Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; Registrational
Sponsors Vertex Pharmaceuticals

Most Recent Events

25 Jan 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
17 Jan 2023 Status changed from active, no longer recruiting to completed.
30 Jun 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com